RIGBY JONATHAN 4

What Happened
Jonathan Rigby, a director of Oncolytics Biotech Inc. (ONCY), received a grant of options covering 30,000 shares on June 1, 2026. The Form 4 shows the acquisition price as $0.00; a filing footnote clarifies the option exercise price equals the closing price of ONCY common stock on Nasdaq on June 1, 2026, so the award has no reported immediate in‑the‑money value.

Key Details

• Transaction date: June 1, 2026; Form 4 filed June 3, 2026.
• Transaction type: Award/Grant of derivative securities (code A) — 30,000 option shares.
• Price/Value reported on form: $0.00 (see footnote: actual exercise price = closing market price on 2026-06-01).
• Vesting: Options vest in three equal annual installments; first vesting date June 1, 2027, subject to continued service (per footnote).
• Shares owned after transaction: Not specified in the provided filing summary.
• Filing timeliness: Filed two days after the grant date (no late-filing indication in the provided data).

Context

• This was a time‑based option grant (equity compensation) rather than a market purchase or sale; such grants compensate or retain directors and do not by themselves signal buying/selling conviction.
• Because the exercise price is set at the market close on the grant date, the options were at-the-money at grant (no immediate intrinsic value).
• No immediate sale or cashless exercise was reported.